Third member of U.S. FDA advisory panel resigns over Alzheimer’s drug approval

Published by
Reuters

By Julie Steenhuysen and Carl O’Donnell (Reuters) – A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so. Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel. “My rationale was that the FDA needs to re-evaluate how it solicits and uses the advi…

Read More

Share this Story
Load More Related Articles
Load More In US News

Facebook Comments

Check Also

Removal of foreign fighters in Libya tops agenda at Berlin conference

Published by DPA The foreign ministers of the ...

Archives